Sexual Dysfunction

O’Leary discusses safety related to instillation of the Penuma penile enhancement implant.

Compared with single men, those in this age group who were married/partnered had 65% lower odds of having ED.

Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss trends in reimbursement for men's health procedures from 2002 to 2020.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

The findings support continued investigation of the safety and efficacy of mirabegron in men with OAB and concurrent ED, says study author Arthur L. Burnett, II, MD, MBA.

Men using the RestoreX traction device saw a median 1.6-cm increase in length at 6 months, versus a median of 0.3 to 0.7 cm for controls.

Christopher Warren discusses steps urologists can take to create and/or share patient education videos regarding Peyronie disease.

Men who receive care for erectile dysfunction from their primary care provider are much less likely to receive advanced pharmacological therapies for management of their condition than those treated by urologists.

Ranjith Ramasamy, MD, discusses a recent study evaluating the testosterone nasal gel Natesto.

"While we generally don’t perform surgery for PD in the first year, it makes sense to treat these patients earlier with intralesional collagenase clostridium histolyticum," says Wayne J.G. Hellstrom, MD.

Retreatment rates were low with both aquablation and transurethral resection of the prostate.

In patients with prior exposure to PDE5 inhibitors, increasing the number of sessions of low-intensity shockwave therapy was associated with improving outcomes.

Trinity Bivalacqua, MD, PhD, discusses the available evidence for the use of restorative therapies for erectile dysfunction.

The AUA 2018 sexual dysfunction take-home messages also included a novel end-to-side nerve grafting procedure for men with post-radical-prostatectomy ED as well as the finding that use of a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor does not appear to change the adverse effect profile of flibanserin (Addyi).

To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.

In this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.

There are no national or international guidelines regarding penile transplants, raising a question without a concrete answer: What are the rules and the limits?

"[Penile transplantation] is a real advance for patients who have a penile deficiency or penile loss," says Arthur L. Burnett, II, MD, MBA.

While urologists are generally comfortable discussing patients’ sexual orientation, they report that both their knowledge of care of transgender patients and training in such care are lacking.

It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.

Other products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.

Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.

Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more

Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.